Affiliation at the time of substantial contribution.
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
Version of Record online: 4 OCT 2013
© 2013 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Pediatric Blood & Cancer
Volume 61, Issue 4, pages 636–642, April 2014
How to Cite
Robison, N. J., Campigotto, F., Chi, S. N., Manley, P. E., Turner, C. D., Zimmerman, M. A., Chordas, C. A., Werger, A. M., Allen, J. C., Goldman, S., Rubin, J. B., Isakoff, M. S., Pan, W. J., Khatib, Z. A., Comito, M. A., Bendel, A. E., Pietrantonio, J. B., Kondrat, L., Hubbs, S. M., Neuberg, D. S. and Kieran, M. W. (2014), A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr. Blood Cancer, 61: 636–642. doi: 10.1002/pbc.24794
Conflict of interest: Nothing to declare.
Prior presentation: Preliminary data from this study were presented in part at the 43rd Congress of the International Society of Pediatric Oncology, October 26–30, 2011, Auckland, New Zealand and at the 15th International Symposium on Pediatric Neuro-Oncology, June 24–27, 2012, Toronto, Canada.
- Issue online: 6 FEB 2014
- Version of Record online: 4 OCT 2013
- Manuscript Accepted: 4 SEP 2013
- Manuscript Received: 13 JUN 2013
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Stop & Shop Pediatric Brain Tumor Research Fund
- Pediatric Brain Tumor Research and Clinical Fund Support for data management was provided by Celgene Pharmaceutical Corporation
Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
|pbc24794-sm-0001-SuppTab-S1.docx||16K||Supplemental Table I.|
|pbc24794-sm-0001-SuppTab-S2.docx||23K||Supplemental Table II.|
|pbc24794-sm-0001-SuppTab-S3.docx||15K||Supplemental Table III.|
|pbc24794-sm-0001-SuppTab-S4.docx||37K||Supplemental Table IV.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.